SCHEMBL460676

SCHEMBL460676

CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)N1CCc2cc(-c3ccc([C@H]4CC[C@H](CC(=O)O)CC4)cc3)ccc21

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 8/20 0.56
UCHL1 P09936 11/20 0.49
USP30 Q70CQ3 4/20 0.46
SOAT2 O75908 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL460677 1.00 DGAT1 (0.56) DGAT1UCHL1USP30SOAT2
SCHEMBL460678 1.00 DGAT1 (0.56) DGAT1UCHL1USP30SOAT2
SCHEMBL10258511 0.92 UCHL1 (0.49) DGAT1UCHL1USP30
SCHEMBL10197562 0.92 UCHL1 (0.49) DGAT1UCHL1USP30
SCHEMBL13190608 0.89 UCHL1 (0.55) UCHL1USP30
SCHEMBL382919 0.83 DGAT1 (0.54) DGAT1UCHL1USP30SOAT2
SCHEMBL382918 0.83 DGAT1 (0.54) DGAT1UCHL1USP30SOAT2
SCHEMBL10197151 0.77 DGAT1 (0.69) DGAT1SOAT2
SCHEMBL10260835 0.77 DGAT1 (0.69) DGAT1SOAT2
SCHEMBL410404 0.76 DGAT1 (0.68) DGAT1SOAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE SCHERING CORPORATION (US) 2012-01-26 US disclosed
EP-2408744-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE Schering Corporation (US) 2012-01-25 EP disclosed
WO-2010107768-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE SCHERING CORPORATION (US) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE DGAT2, DGAT1, LCAT DGAT1 2/4885UCHL1 3297/4885USP30 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.